Efficacy of once-weekly tirzepatide versus once-daily insulin degludec on glycaemic control measured by continuous glucose monitoring in adults with type 2 diabetes (SURPASS-3 CGM): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial

医学 脱胶胰岛素 二甲双胍 2型糖尿病 糖尿病 胰岛素 内科学 相伴的 连续血糖监测 随机对照试验 内分泌学 血糖性 基础胰岛素
作者
Tadej Battelino,Richard M. Bergenstal,Ángel Rodríguez,Laura Fernández Landó,Ross Bray,Zhentao Tong,Katelyn Brown
出处
期刊:The Lancet Diabetes & Endocrinology [Elsevier BV]
卷期号:10 (6): 407-417 被引量:56
标识
DOI:10.1016/s2213-8587(22)00077-8
摘要

Background Tirzepatide is a novel dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist under development for the treatment of type 2 diabetes. In this study, we used continuous glucose monitoring (CGM) to compare the 24 h glucose profile for participants given tirzepatide compared with those given insulin degludec. Methods This substudy of the open-label, parallel-group, phase 3 SURPASS-3 trial, was done at 45 sites across six countries (Hungary, Poland, Romania, Spain, Ukraine, and the USA). Eligible participants in the main study were adults with type 2 diabetes, a baseline HbA1c of 7·0–10·5% (53–91 mmol/mol), and a BMI of 25 kg/m2 or more, who were insulin-naive, and treated with metformin alone or in combination with a SGLT2 inhibitor for at least 3 months before screening. Participants in the main study were randomly assigned (1:1:1:1) to receive once-weekly subcutaneous injection of tirzepatide 5 mg, 10 mg, or 15 mg, or once-daily subcutaneous injection of titrated insulin degludec (100 U/mL), using an interactive web-response system. Participants were stratified by country, HbA1c concentration, and concomitant oral antihyperglycaemic medication. A subset of these patients with a normal wake–sleep cycle were enrolled into this substudy, and interstitial glucose values were collected by CGM for approximately 7 days at baseline, 24 weeks, and 52 weeks. The primary outcome was to compare pooled participants assigned to 10 mg and 15 mg tirzepatide versus insulin degludec for the proportion of time that CGM values were in the tight target range (71–140 mg/dL) at 52 weeks, assessed in all randomly assigned participants who received at least one dose of study drug and had an evaluable CGM session at either baseline or after baseline. The secondary outcomes were to compare tirzepatide (5 mg, 10 mg, and 15 mg) versus insulin degludec for the proportion and duration of time in tight target range at 24 and 52 weeks. This was a substudy of the trial registered with ClinicalTrials.gov, NCT03882970, and is complete. Findings From April 1 to Nov 27, 2019, 313 participants were screened for eligibility, 243 of whom were enrolled in CGM substudy (tirzepatide 5 mg, n=64; tirzepatide 10 mg, n=51; tirzepatide 15 mg, n=73; and insulin degludec, n=55). Patients given once-weekly tirzepatide (pooled 10 mg and 15 mg groups) had a greater proportion of time in tight target range compared with patients given insulin degludec (estimated treatment difference 25% [95% CI 16–33]; p<0·0001). Participants assigned to tirzepatide spent significantly more time in tight target range at 52 weeks compared with those assigned to insulin degludec (5 mg 12% [1–22], p=0·031; 10 mg 24% [13–35], p<0·0001; and 15 mg 25% [14–35], p<0·0001). Participants assigned to tirzepatide 10 mg and 15 mg, but not to tirzepatide 5 mg, spent significantly more time in tight target range at 24 weeks compared with insulin degludec (10 mg 19% [8–30], p=0·0008; 15 mg 21% [11–31], p<0·0001). Interpretation Once-weekly treatment with tirzepatide showed superior glycaemic control measured using CGM compared with insulin degludec in participants with type 2 diabetes on metformin, with or without a SGLT2 inhibitor. These new data provide additional evidence to the effect of tirzepatide and potential for achieving glycaemic targets without increase of hypoglycaemic risk compared with a basal insulin. Funding Eli Lilly and Company.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
煎饼煎饼发布了新的文献求助20
1秒前
Holmes发布了新的文献求助10
2秒前
张丽丽完成签到,获得积分20
2秒前
简单紫寒发布了新的文献求助20
2秒前
2秒前
null的应助被Carrie采纳,获得10
3秒前
1461644768完成签到,获得积分10
3秒前
Tayzon发布了新的文献求助10
3秒前
4秒前
Nefilibata发布了新的文献求助10
4秒前
Jasper的应助被lq采纳,获得10
4秒前
5秒前
GoldenLee发布了新的文献求助10
6秒前
C大人发布了新的文献求助10
6秒前
7秒前
qiuyu发布了新的文献求助10
7秒前
IIT一根草发布了新的文献求助10
7秒前
南天七发布了新的文献求助20
8秒前
8秒前
777发布了新的文献求助10
9秒前
sjy发布了新的文献求助10
9秒前
Orange的应助被wards采纳,获得10
9秒前
Unicorn_1完成签到,获得积分10
9秒前
cui发布了新的文献求助10
10秒前
10秒前
小橙完成签到 ,获得积分10
10秒前
10秒前
水煮电吹风的应助被Nefilibata采纳,获得10
10秒前
CY完成签到,获得积分10
11秒前
野福发布了新的文献求助10
12秒前
12秒前
12秒前
ding的应助被科研通管家采纳,获得10
13秒前
无极微光的应助被科研通管家采纳,获得20
13秒前
13秒前
桐桐的应助被科研通管家采纳,获得10
13秒前
Tayzon完成签到,获得积分10
13秒前
搜集达人的应助被科研通管家采纳,获得10
13秒前
13秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
Grapes 1000
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8178582
求助须知:如何正确求助?哪些是违规求助? 9569391
关于积分的说明 21804062
捐赠科研通 7773535
什么是DOI,文献DOI怎么找? 3432871
关于科研通互助平台的介绍 2556860
邀请新用户注册赠送积分活动 2478451